Related Experiment Video

Updated: Jun 27, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.2K

EGC enhances tumor antigen presentation and CD8+ T cell-mediated antitumor immunity via targeting oncoprotein SND1

Xinxin Zhang1, Xiaoteng Cui2, Peiying Li1

  • 1Tianjin Key Laboratory of Cellular and Molecular Immunology, and Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin, China; The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, Tianjin, China; State Key Laboratory of Experimental Hematology, Tianjin, China; Department of Biochemistry and Molecular Biology, Department of Immunology, School of Basic Medical Science, Tianjin Medical University, Tianjin, China.

Cancer Letters
|May 6, 2024
PubMed

Insights

We identified (-)-Epigallocatechin (EGC) as a novel inhibitor that blocks the oncoprotein SND1 from binding to MHC-I. This enhances tumor immunotherapy by improving T cell responses against cancer.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Staphylococcal nuclease and Tudor domain containing 1 (SND1) is an oncoprotein that hinders major histocompatibility complex class I (MHC-I) presentation.
  • SND1 targets MHC-I heavy chains for degradation, reducing cancer cells' ability to display antigens.

Purpose of the Study:

  • To identify inhibitors that disrupt the SND1-MHC-I interaction.
  • To enhance MHC-I presentation for improved tumor immunotherapy.

Main Methods:

  • Structure-based virtual screening and docking analysis identified potential inhibitors.
  • In vitro assays assessed the effect of inhibitors on MHC-I expression.
  • Murine melanoma models evaluated anti-tumor efficacy and T cell responses.
  • Combination therapy with PD-1 antibody was tested.

Main Results:

  • (-)-Epigallocatechin (EGC) showed high binding affinity, preventing SND1-MHC-I interaction by altering SND1 conformation.
  • EGC treatment increased membrane-bound MHC-I expression in tumor cells.
  • EGC enhanced CD8+ T cell infiltration and activity in tumors and spleens.
  • Combined EGC and PD-1 antibody treatment yielded superior anti-tumor effects.

Conclusions:

  • EGC is a novel inhibitor of the SND1-MHC-I interaction.
  • EGC enhances MHC-I presentation, boosting CD8+ T cell responses.
  • EGC represents a promising immunotherapeutic candidate for cancer treatment.
Keywords:
CD8(+) T cellsEGCMHC-I heavy chainSND1Structure-based virtual screening

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.6K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
901
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
709